Adults 21 to 70, any sex, with Alcohol Use Disorder. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Stimulant Effects of Alcohol When Co-administered With Drug or Matching PlaceboPrimary· Twice at each laboratory session, visits 2 and 3, during the ascending and descending phase of alcohol administration (BrAC).
The stimulant effect of alcohol is assessed using the Biphasic Alcohol Effects Scale (BAES).
The BAES is a self-report, unipolar adjective rating scale that is designed to measure both stimulant and sedative effects of alcohol. It consists of 14 items (score) that are rated on a 11-point scale. 7 of the 14 items comprise the stimulation subscale. Individuals are instructed to rate the extent to which alcohol has produced these feelings at the present time from minimum=0 to maximum=10. The subscale of stimulation has a minimum score of 0 (not at all, best outcome) and a maximum score of 70 (hi
Ascending alcohol BrAC
Group
Value
95% CI
Matching Placebo
28.23
± 21.82
Probenecid
25.26
± 20.66
Descending alcohol BrAC
Group
Value
95% CI
Matching Placebo
20.57
± 18.95
Probenecid
19.56
± 20.33
Sedative Effects of Alcohol When Co-administered With Drug or Matching PlaceboSecondary· Twice at each laboratory session, visits 2 and 3, during the ascending and descending phase of alcohol administration (BrAC).
The sedative effect of alcohol is assessed using the Biphasic Alcohol Effects Scale (BAES).
The BAES is a self-report, unipolar adjective rating scale that is designed to measure both stimulant and sedative effects of alcohol. It consists of 14 items (score) that are rated on a 11-point scale. 7 of the 14 items comprise the sedation subscale. Individuals are instructed to rate the extent to which alcohol has produced these feelings at the present time from minimum=0 to maximum=10. The subscale of stimulation has a minimum score of 0 (not at all, best outcome) and a maximum score of 70 (high,
Ascending limb of BrAC
Group
Value
95% CI
Matching Placebo
16.02
± 14.21
Probenecid
16.79
± 15.17
Descending limb of BrAC
Group
Value
95% CI
Matching Placebo
16.26
± 15.27
Probenecid
16.50
± 15.15
Alcohol CravingSecondary· Twice at each laboratory session, visits 2 and 3, during the ascending and descending phase of alcohol administration (BrAC).
Alcohol craving is assessed using change in the alcohol urge questionnaire (AUQ).
The Alcohol Urge Questionnaire (AUQ) consists of eight statements about the respondent's feelings and thoughts about drinking as they are completing the questionnaire (i.e., right now). Drinking refers to various types of alcohol, including beer, wine and liquor. The respondent is asked to respond to each statement about alcohol craving via a 7-item Likert scale ranging from "strongly disagree" to "strongly agree." Each item is scored on a 1 to 7 scale (Strongly Disagree = 1 and Strongly Agree = 7). Items 2 and
Ascending limb of BrAC
Group
Value
95% CI
Matching Placebo
23.09
± 13.23
Probenecid
17.24
± 10.47
Descending limb of BrAC
Group
Value
95% CI
Matching Placebo
19.63
± 12.04
Probenecid
18.38
± 12.29
Sponsor's own description
The design is a randomized, within-subject, crossover, double-blind, placebo-controlled human alcohol laboratory study with one oral dose of 2g probenecid or placebo administered in two laboratory sessions.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06860607 — Environment and Alcohol: A Pilot Study
· Phase 1
· recruiting
NCT07325266 — Human Laboratory Study of Apremilast for Alcohol Use Disorder
· Phase 2
· recruiting
NCT07046819 — Tirzepatide in MetALD
· Phase 2
· recruiting
NCT07279558 — Cannabidiol and Alcohol Use Disorder Phenotypes
· Phase 2
· recruiting
NCT07056894 — Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis
· NA
· recruiting
Other Brown University trials
Trials by the same sponsor.
NCT07502872 — TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-g
· Phase 2
· not yet recruiting
NCT07118618 — Probenecid Administration for Alcohol Craving and Consumption
· Phase 2
· recruiting
NCT07398443 — Using Novel Behavioral Economic Measures to Characterize Dual Marijuana and Tobacco Use in Young Adults
· NA
· recruiting
NCT05901766 — Effect of Iodine-containing Multiple Micronutrient During Lactation on Infant Neurodevelopment
· Phase 4
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Brown University
Last refreshed: 27 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04218357.